Award of NHS Framework for Branded Medicines and Insulin Aspart Biosimilar in England

About

NHS England awarded a contract to Thornton and Ross Ltd, Janssen-Cilag Ltd, Biogen, Merck Serono Limited, Celltrion Healthcare United Kingdom Limited, Bristol Myers Squibb, AstraZeneca, UL Global Pharma, GlaxoSmithKline UK Limited, and Roche Produ for the supply of branded medicines and insulin aspart biosimilar (Trurapi®) across various regions of England.

The contract value is £238,913,892.

The framework includes multiple tranches: Tranche B for the North of England from 1 March 2022 to 29 February 2024 with extension options up to 24 months; Annual Tranche Products from 1 March 2022 to 28 February 2023 with extension options up to 12 months; and Insulin Aspart Biosimilar (Trurapi®) for the South of England (1 March 2022 to 31 August 2022), London (1 March 2022 to 31 August 2023), and Midlands and East (1 March 2022 to 28 February 2023), each with extension options up to 24 months.